Perfusion Bioreactor Market

Perfusion Bioreactor Market Highlights

The global perfusion bioreactor market is expected to cross a value of USD 708.3 million by the end of 2032. The market was valued at USD 351.2 million in 2023 and is expected to expand at a CAGR of 7.5% between 2024-2032.

• Over the mid-term, the rise in adoption of single-use bioreactors is the primary factor anticipated to drive the global perfusion bioreactor market.
• The growing concern for complex operational procedure is a major factor to challenge the market growth.
• The North America perfusion bioreactor market is projected to dominate the global market.

Perfusion Bioreactor Market Outlook

In the biopharmaceutical industry, a perfusion bioreactor is used for cultivating and growing cells, tissues or microorganisms under controlled conditions. These bioreactors supply fresh media continuously for cell growth and also removes the spent media and metabolic byproducts.

Our analysts at KD Market Insights have analyzed that the global market for perfusion bioreactors is expected to grow on account of the rise in adoption of single-use bioreactors, supported by the expanding pharmaceutical and biotechnology industry. Moreover, the growing demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and cell-based therapies, is also expected to drive the demand for perfusion bioreactors, and in turn, contribute to the market growth. Sartorius AG, Cell Culture Company, and Cytiva (Danaher Corporation) are some of the significant parties in the global market for perfusion bioreactor.

                              Get More Insights on This Report - Request Free Sample PDF

Perfusion Bioreactor Market Drivers – Analyst’s Observation

According to the analysts at KD Market Insights, some key growth drivers for the global perfusion bioreactor market are:

• Growing Advancements in Cell and Gene Therapy: The field of cell and gene therapy is experiencing rapid growth globally. With the increasing number of therapies entering clinical development and gaining regulatory approval, which according to the United States Food and Drug Administration, witnessed approval of 37 novel drugs in 2022, the demand for perfusion bioreactors is expected to increase. These bioreactors play a crucial role in the manufacturing of cell-based therapies, such as CAR-T cell therapy and stem cell therapies, and hence the increasing demand for the product.
• Rapid Focus on Continuous Bioprocessing in the Biopharmaceutical Industry: In the biopharmaceutical industry, the process of continuous bioprocessing is being adopted rapidly owing to the numerous benefits associated with it, such as, enhanced efficiency, reduce costs, and improved product consistency. Perfusion bioreactors enable continuous cell culture operations, allowing for uninterrupted production and higher throughput compared to batch processes. Hence, the demand for these bioreactors are expected to grow massively.

Which Probable Factors Could Hamper the Growing Perfusion Bioreactor Market Trend?

As per our KD Market Insights analysis, some of the challenges expected to limit the global market growth of perfusion bioreactor are:

• Concern for Complex Operational Procedures: Perfusion bioreactors require specialized expertise for operation, maintenance, and troubleshooting. Ensuring proper setup, calibration, and sterility of the system can be challenging, particularly for users without extensive experience in cell culture and bioprocessing.
• Stringent Regulatory Requirements: Biopharmaceutical manufacturing processes, including those using perfusion bioreactors, are subject to stringent regulatory requirements imposed by health authorities such as the FDA (Food and Drug Administration) and EMA (European Medicines Agency). Compliance with Good Manufacturing Practices (GMP) and other regulatory standards necessitates thorough documentation, validation, and quality control measures, which can increase the time and cost of bringing products to market. Such a factor is therefore predicted to hinder the growth of the perfusion bioreactor market.

How is the Global Perfusion Bioreactor Market Segmented?

Our experts at KD Market Insights have segmented the global perfusion bioreactor market as:

What are the Probable Factors Influencing the North America Perfusion Bioreactor Market Forecast?

The North America perfusion bioreactor market is majorly driven by the presence of a strong healthcare and biopharmaceutical industry, followed by the surge in demand for biopharmaceuticals, supported by the expanding capacity of manufacturers of biopharmaceuticals. The North American region is witnessing a higher demand for monoclonal antibodies, vaccines, and cell-based therapies, which is driving the demand for perfusion bioreactors. Moreover, the region’s pharmaceutical companies, contract manufacturing organizations (CMOs), and academic institutions are investing heavily in expanding the bio manufacturing capacity to meet the rising demand for biologics. Our researchers predict that the revenue generated from the sales of biologics in North America is poised to touch USD 557.6 billion by the end of 2032, registering a CAGR of about 6.4% during the forecast period.

As per our analysts at KD Market Insights, the following five players lead the North America perfusion bioreactor market growth:

• Repligen Corporation
• Merck KGaA (MilliporeSigma)
• Thermo Fisher Scientific Inc.
• Sartorius AG
• GE Healthcare

Which Key Players Top the Global Perfusion Bioreactor Market Share?

As per our analysts at KD Market Insights, the competitive landscape of global perfusion bioreactor market facilitates our readers in identifying their closest competitors. The manufacturers who are associated with perfusion bioreactor market are raising their focus on expanding their presence, as well as their market share. The market has also been witnessing an upward movement in the number of collaborations between research institutions and key players, aimed at introducing advanced technologies and innovation of new products. Here is a list of the key players who top the global perfusion bioreactor market share:

• Sartorius AG
• Cell Culture Company
• Cytiva (Danaher Corporation)
• CELLEC BIOTEK AG
• Synthecon Inc
• Getinge (Applikon Biotechnology B.V)
• Zellwerk GmbH
• Thermo Fisher Scientific Inc
• Eppendorf AG
• Infors HT
• 3D Biotek LLC

What are the Recent Developments Observed in the Perfusion Bioreactor Market?

Over the years, the experts at KD Market Insights have been observing the recent developments associated with global perfusion bioreactor market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

For instance, Thermo Fisher Scientific announced that it has opened a new bioprocessing collaboration center for accelerating innovation in biologics in St. Louis, United States.

Further, Sartorius stated that it has acquired the life science companies of Danaher Corporation.